Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
EthR2 (Probable transcriptional regulatory protein Rv0078) is a TetR-family transcriptional repressor in Mycobacterium tuberculosis that regulates the expression of the alternative ethionamide-activating monooxygenase EthA2 (also known as MymA). Ethionamide is a crucial second-line prodrug used to treat multidrug-resistant tuberculosis, but its clinical utility is severely limited by dose-dependent hepatotoxicity and gastrointestinal side effects, as well as the rapid emergence of resistance mutations in its primary activating enzyme, EthA. By binding to and inhibiting EthR2, small-molecule adjuvants (such as alpibectir or SMARt-420) induce a conformational change that prevents EthR2 from binding to its target DNA. This derepresses the alternative activation pathway, allowing EthA2/MymA to bioactivate ethionamide into its active form. Consequently, this booster strategy dramatically increases the potency of ethionamide, allowing for a significant reduction in the therapeutic dose and overcoming established EthA-mediated drug resistance.
Inhibition of the EthR2 transcriptional repressor, which derepresses the expression of the alternative monooxygenase EthA2 (also known as MymA). This increases the bioactivation of the prodrug ethionamide into its active sulfoxide metabolite, thereby potentiating ethionamide efficacy and overcoming resistance caused by mutations in the primary activating enzyme EthA.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Probable transcriptional regulatory protein Rv0078 (EthR2).